Efficacy and safety of Chinese medicine for obstructive sleep apnea: A protocol for systematic review and meta-analysis

Medicine (Baltimore). 2021 Jan 22;100(3):e23903. doi: 10.1097/MD.0000000000023903.

Abstract

Background: Obstructive sleep apnea (OSA) is significant public concern. Clinical practice indicates that Chinese medicine has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of Chinese medicine for OSA.

Methods: Data in PubMed, Embase, Web of Science, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSA children were identified, in which the effects of Chinese medicine on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.

Results: The efficacy and safety of Chinese medicine for OSA were evaluated in terms of apnea hypopnea index (AHI, the average and lowest blood oxygen, the Epworth Sleep Scale [ESS], and adverse effects).

Conclusions: This study provides reliable evidence-based support for the clinical application of Chinese medicine for OSA.

Prospero registration number: CRD42020154864.

MeSH terms

  • Drugs, Chinese Herbal* / therapeutic use
  • Humans
  • Meta-Analysis as Topic
  • Randomized Controlled Trials as Topic
  • Sleep Apnea, Obstructive* / drug therapy
  • Systematic Reviews as Topic
  • Treatment Outcome

Substances

  • Drugs, Chinese Herbal